Clinical trial
An International, Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
NCT00128505 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An International, Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
- Lead sponsor
- Corcept Therapeutics
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2005
- Completion date
- November 30, 2006
- Enrollment
- 104 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.